Short communication · Oct 2020
Conference abstractPublished 12 Sep 2016
Protein S, a new agent in adjunct therapy of hemophilia-B
LSU Health Science Center, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Current treatment of hemophilia-B consists of infusion of factor IX (FIX) concentrates to substitute for deficient FIX, i.e., replacement therapy. Yet, replacement is only temporary, as infused FIX is cleared rapidly from a patient’s plasma. We found that Protein S (PS) inhibits FIX and importantly, anti-PS antibody increased FIX activity in hemophilia-B plasma, implying that blocking PS activity may achieve longer lasting replacement therapy. Aims: To assess the effectiveness of anti-PS antibody in reducing clotting time. Method & Results: We used a modified aPTT assay (clotting initiated with FIX) with FIX-deficient plasma and varied the concentrations of added FIX and anti-PS antibody. The aPTT clotting times in the presence and absence of anti-PS antibody were measured for 2.5 (51 sec+Ab; 69 sec+Ab), 5 (43 sec+Ab; 59 seconds+Ab), 10 (38 sec+Ab; 51 sec+Ab), and 20 nM FIXa (33 sec+Ab; 40 sec+Ab). Results showed that in FIX-deficient plasma, an anti-PS antibody would make added FIXa ~3 fold more active. We also performed a thrombin generation assay with the same FIX-deficient plasma in the presence of 1, 2.5 and 5 nM FIXa and measured peak thrombin formation in the presence of anti-PS antibody. Both the thrombin generation assay and the clotting assay gave similar results, i.e., addition of neutralizing anti-PS antibody made FIX ~3 fold more active. In wild type mice we have found that PS inhibited thrombin generation. Work is underway to assess hemostasis in hemophilia-B mice receiving a low dose of FIX and PS antibodies. Improved hemostasis in this mouse model would move anti-PS antibody to the forefront as a possible adjunct in hemophilia therapy. Conclusion: Our findings suggest that administration of anti-PS antibodies to hemophilia-B patients may achieve the goal of longer lasting replacement therapy. Antibody blocking PS activity towards FIXa is the most straightforward approach and one most likely to succeed.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2017
Efficacy of adjunct (laser) therapy to topical agents among Southern Nigeria acne vulgaris patients
Conference abstract · 20 Jul 2015
Efficacy of adjunct (laser) therapy to topical agents among southern nigerian acne vulgaris patients
Research article · 2014
Study of a New Gliadin Capture Agent and Development of a Protein Microarray as a New Approach for Gliadin Detection
Conference abstract
Unfolded protein response (UPR) signalling in anti-angiogenic therapy for patients with breast cancer resistance to current anti-VEGF agents
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Rinku Majumder”
